News about "CDMO"

Agno Pharma Acquires Actylis's CDMO Manufacturing Asset

Agno Pharma has acquired Actylis’s CDMO manufacturing asset, the legacy Cascade Chemistry business based in Eugene, Oregon, strengthening Agno’s U. cGMP API development and manufacturing capabilities.

CDMO | 19/01/2026 | By News Bureau

Rakuten Medical and LOTTE Biologics Sign Manufacturing Deal for Global Oncology Programme

Rakuten Medical has entered into a manufacturing agreement with LOTTE Biologics under which LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates, supporting Rakuten Medical’s global clinical development programmes and future commercialisation in oncology.

CDMO | 19/01/2026 | By News Bureau

Transcenta Therapeutics Signs Strategic Biomanufacturing Collaboration and Licensing Deal with EirGenix

Under the agreement, Transcenta will grant EirGenix a non-exclusive licence to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages.

CDMO | 30/12/2025 | By News Bureau

PharmAla Biotech Australia Ties Up with UK CDMO to Manufacture ALA-002

PharmAla Biotech Australia has contracted a UK-based CDMO to manufacture the drug substance for ALA-002, its patented non-racemic MDMA formulation, ahead of planned phase 2a/2b clinical trials for social anxiety disorder expected to begin in 2026.

CDMO | 16/12/2025 | By News Bureau

Indian Pharmaceutical Alliance Welcomes New Leadership

Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, and Vice President, Indian Pharmaceutical Alliance (IPA), has been appointed President of the alliance, while Glenn Saldanha, Chairman and Managing Director, Glenmark, will serve as the new Vice President.

CDMO | 04/10/2025 | By Dineshwori |  154

Akums Becomes First Indian CDMO to Receive DCGI Approval for Innovative Glaucoma Treatment

Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden.

CDMO | 01/04/2025 | By Abha |  417

Kincell Bio Appoints New Chief Executive Officer to Drive Business Growth

Mark, who has served as Chair of the Board since May 2024, brings decades of industry experience to the role and will be pivotal in advancing Kincell Bio’s mission to support innovators in the rapidly growing cell therapy sector.

CDMO | 21/01/2025 | By Aishwarya |  217

Glenmark Life Sciences Rebrands its Identity as Alivus Life Sciences

The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus.

CDMO | 20/01/2025 | By Aishwarya |  2651

OneSource Secures Equity Commitments of USD 95 Million for Fundraising

The strong interest from leading investors reflects growing confidence in our capabilities and the immense potential of the CDMO sector emerging out of India.

CDMO | 16/10/2024 | By Aishwarya |  545

Agilent Announces Acquisition of BIOVECTRA

With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add rapidly growing modalities, and bring world-class capabilities to support gene editing.

CDMO | 24/09/2024 | By Aishwarya |  506